Disclaimer

The alfapump® system is currently not approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.

Tag

Regulated
PRESS RELEASE REGULATED INFORMATION 27 April 2021, 07:00 am CEST   Publication of Annual Report 2020 Ghent, Belgium, 27 April 2021 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today invites the holders of...
Read More
PRESS RELEASE REGULATED INFORMATION 25 March 2021, 06:00 pm CET   Ghent, Belgium, 25 March 2021 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, announces, in accordance with Article 15 of the Belgian Act...
Read More
PRESS RELEASE REGULATED INFORMATION 17 March 2021 07:00 CET                 POSEIDON – positive interim results in Q4 2020; additional interim results expected in Q2 2021 and primary endpoint in Q2 2022 RED DESERT – positive interim results in Q4 2020; top-line data expected in Q2 2021 Successful equity placements extend cash runway into Q2...
Read More
Regulated information 23 February 2021, 06:00 pm CET Ghent, BELGIUM – 23 February 2021 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, announces today in accordance with Article 14 of the Belgian Act of...
Read More
PRESS RELEASE REGULATED INFORMATION 16 February 2021, 07:00 am CET   Ghent, Belgium, 16 February 2021 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, announces, in accordance with Article 15 of the Belgian Act...
Read More
Ghent, BELGIUM – 25 June 2020 – Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, announces today that 644,287 existing shares have been admitted to listing and trading on the regulated market of Euronext Brussels. The...
Read More
PRESS RELEASE – 28 May 2020, 06:00 PM CEST REGULATED INFORMATION Ghent, BELGIUM – 28 May 2020 – Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, announces that all proposed resolutions submitted to the Annual and...
Read More
PRESS RELEASE 28 April 2020 07:00 CEST REGULATED INFORMATION   Publication of Annual Report 2019 Ghent, BELGIUM – 28 April 2020 – Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today invites the holders of securities...
Read More
PRESS RELEASE 19 MARCH 2020 07:00 CET REGULATED INFORMATION   Continued strong progress in U.S. NASH-related and global heart failure programmes Successfully raised €19 million in Q1 2020 extending cash runway into H1 2021 Conference call with live webcast presentation today at 14:00 CET / 09:00 ET   Ghent, BELGIUM – 19 March 2020 –...
Read More
Regulated Information Ghent, BELGIUM – 21 February 2020 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces in accordance with article 14 of the Belgian Act of 2 May 2007 on the disclosure of...
Read More
1 5 6 7 8 9

PRESS RELEASES

SUBSCRIBE TO OUR PRESS RELEASES